1. A5.10 Increases in serum cholesterol with baricitinib treatment are associated with favourable changes in apolipoprotein content and with improvement in DAS28-CRP in patients with rheumatoid arthritis. (13th February 2015) Authors: Kremer, J; Genovese, MC; Keystone, E; Taylor, P; Zuckerman, SH; Schlichting, DE; Nantz, E; Beattie, SD; Macias, WL Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 1 Page Start: A51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A7.17 Effects of baricitinib on multibiomarker disease activity scores and their components in a phase 2b study in moderate-to-severe rheumatoid arthritis patients. (24th February 2016) Authors: Taylor, PC; Genovese, MC; Keystone, E; Weinblatt, M; Rancourt, J; Nantz, E; Schlichting, DE; Zuckerman, SH; Macias, WL Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 1 Page Start: A62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A8.5 Baricitinib effects on serum cholesterol and circulating lipid particles in a phase 2B study in patients with rheumatoid arthritis. (13th February 2015) Authors: Kremer, J; Genovese, MC; Keystone, E; Taylor, P; Zuckerman, SH; Schlichting, DE; Beattie, SD; Macias, WL Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 1 Page Start: A83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0068 102-wk clinical and radiologic results from the attract trial: a 2 year, randomised, controlled, phase 3 trial of infliximab (remicade®) in pts with active ra despite mtx. (1st June 2001) Authors: Maini, R; Van der Heijde, D; Smolen, J; Kalden, J; Breedveld, F; Emery, P; Keystone, E; Harriman, G; Lipksy, P Journal: Annals of the rheumatic diseases Issue: Volume 60(2001)Supplement 1 Page Start: A473 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0092 Effects of baricitinib on haemoglobin and related laboratory parameters in rheumatoid arthritis patients. (15th June 2017) Authors: Kay, J; Harigai, M; Rancourt, J; Dickson, C; Isaka, Y; Chen, L; Carmack, T; Hyslop, D; Muram, D; Macias, W; Bradley, J; Keystone, E Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 513 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FRI0187 Radiographic progression by disease activity states in patients with rheumatoid arthritis treated with sb2 or reference infliximab. (15th June 2017) Authors: Smolen, JS; Choe, J-Y; Keystone, E; Rho, YH; Lee, Y; Lee, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 552 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Issue 11 (14th July 2008) Authors: Emery, P; Keystone, E; Tony, H P; Cantagrel, A; van Vollenhoven, R; Sanchez, A; Alecock, E; Lee, J; Kremer, J Journal: Annals of the rheumatic diseases Issue: Volume 67:Issue 11(2008) Page Start: 1516 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Infliximab in active early rheumatoid arthritis. Issue 2 (13th January 2004) Authors: Breedveld, F C; Emery, P; Keystone, E; Patel, K; Furst, D E; Kalden, J R; St Clair, E W; Weisman, M; Smolen, J; Lipsky, P E; Maini, R N Journal: Annals of the rheumatic diseases Issue: Volume 63:Issue 2(2004) Page Start: 149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor α antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Issue 8 (4th August 2008) Authors: Mease, P J; Hobbs, K; Chalmers, A; El-Gabalawy, H; Bookman, A; Keystone, E; Furst, D E; Anklesaria, P; Heald, A E Journal: Annals of the rheumatic diseases Issue: Volume 68:Issue 8(2009) Page Start: 1247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis. Issue 10 (12th September 2008) Authors: Karonitsch, T; Aletaha, D; Boers, M; Bombardieri, S; Combe, B; Dougados, M; Emery, P; Felson, D; Gomez-Reino, J; Keystone, E; Kvien, T K; Martin-Mola, E; Matucci-Cerinic, M; Richards, P; van Riel, P; Siegel, J; Smolen, J S; Sokka, T; van der Heijde, D; van Vollenhoven, R Journal: Annals of the rheumatic diseases Issue: Volume 67:Issue 10(2008) Page Start: 1365 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗